SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as its strong Q4 earnings, profitability, and new share buyback authorization have ironically led to a significant stock decline, sparking widespread frustration among investors. The community is fiercely debating whether ongoing stock-based compensation and dilution are overshadowing the company's growth in subscriptions and long-term potential in AI/AR smartglasses.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after the abrupt departures of its CFO and General Counsel amid an ongoing accounting review, an SEC investigation, and disclosures of material weaknesses in internal controls and a lowered fiscal outlook. The community is sharply divided, with many voicing deep concerns about potential fraud and a continued decline, while others are aggressively buying the significant dip, anticipating an oversold rebound.

Investment Managers Series Trust II - Tradr 2X Long CRML Daily ETF

Tradr 2X Long CRML Daily ETF

Tradr's recently launched 2X leveraged ETF, $CRMX, tracking Critical Metals ($CRML) and its rare earth projects, is actively discussed as traders debate its actual leverage performance and monitor for a potential breakout from quiet accumulation on increased volume. Many are closely watching its tight consolidation and small float dynamics for an upward move.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE CRYPTO is trending for its notable resilience and positive price action in a challenging market, driven by a dedicated community actively accumulating and promoting its narrative as the "third frog" and literal representation of Pepe by creator Matt Furie. Despite some labeling it a scam, proponents are confident in its organic growth and potential as a prime frog meta beta play.

Dynatrace, Inc. engages in the advancing observability for today’s digital businesses, helping to transform the complexity of modern digital ecosystems into powerful business assets. By leveraging AI-powered insights, Dynatrace enables organizations to analyze, automate, and innovate faster to drive their business forward. The company was founded by Bernd Greifeneder in 2005 and is headquartered in Boston, MA.

Dynatrace Inc

Dynatrace is trending following its strong Q3 fiscal year 2026 earnings report, which surpassed expectations across key metrics and included the authorization of a $1 billion share repurchase program. This positive financial performance and commitment to shareholder returns are fueling optimistic discussions among the community, despite some recent analyst target adjustments.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

OPGN is trending following its strategic pivot to an AI-enabled fintech platform, CapForce, with the community actively discussing an anticipated NASDAQ relisting and the potential for explosive price movements given its extremely low float. Recent compliance filings and strategic acquisitions are fueling optimism for its new direction.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending following its preliminary Q3 FY26 revenue blowout, which significantly surpassed guidance and indicates over 200% YoY growth driven by accelerating AI-driven networking demand. The community is buzzing with bullish sentiment, anticipating a strong rally as the company's crucial role in high-speed, energy-efficient connectivity becomes increasingly recognized after prior market skepticism.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention as recent FDA action against "copycat" GLP-1 compounded drugs highlights the value of legitimate innovation, while strong results from Eli Lilly intensify pressure on competitors like Novo Nordisk, who the community believes urgently need Viking's "best-in-class" VK2735 asset to remain competitive in the rapidly expanding obesity market.

handle.fi is a decentralised multi currency stablecoin protocol which allows users to create and exchange multi-currency stablecoins; called fxTokens. fxTokens are collateral backed stablecoins representing, and soft pegged to, a range of currencies. users create fxTokens by depositing eligible collateral and minting stablecoins secured by this collateral.

handle.fi

FOREX is trending amidst reports of strong trading volumes and industry accolades for major brokers like ATFX, while discussions also focus on significant technological advancements in trading platforms and strategic leadership appointments across the global financial brokerage landscape.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The Invesco DB US Dollar Index Bullish Fund (UUP) is trending as the US dollar faces pressure from widespread expectations of future Fed rate cuts and a broader "risk-on" market sentiment favoring equities and commodities. The community is discussing a potential dollar breakdown, with some linking weakness to de-dollarization concerns and a surge in precious metals like gold and silver.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.5% - Should You Sell?

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.5% - Here's What Happened...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 7.4% Higher - Still a Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.4% - Here's Why...

<ul class="summary-bullets"><li>On Stocktwits, retail sentiment around IOVA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. In the three months through the end of September,</li><li>Iovance reported total product revenue of $68 million, including about $58 million from Amtagvi sales in the U.S.</li><li>In November, the company said that it expects full year 2025 revenue of $250 million to $300 million. &nbsp;</li></ul>Shares of Iovance Biotherapeutics Inc. (IOVA) garnered retail interest on Monday, as shares climbed up 8% amid anticipation from investors for positive announcements, and takeover hopes. &nbsp;On Stocktwits, retail sentiment around IOVA stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.Iovance is a commercial stage immuno-oncology company. It is seeking to deliver tumor-infiltrating lymphocyte (TIL) therapies for patients with cancer. TIL therapy is a personalized, one-time immunotherapy that extracts a patient's own, naturally occurring T-cells from their tumor, expands them to billions in a lab, and infuses them back to fight advanced cancers.<h2 class="st-heading-2">What Do Stocktwits Users Have To Say?</h2>A Stocktwits user highlighted that the company hasn’t made announcements in the recent weeks. “They've had their head down working at the grindstone. Its time for several updates!” they wrote.<stembedurl>https://www.stocktwits.com/BioCrazy1/message/642913966</stembedurl>Another highlighted takeover opportunities.<stembedurl>https://www.stocktwits.com/beachsidefreddy/message/642912870</stembedurl>Another user opined that IOVA management must have a chat with Merck in light of reports that the pharma giant is no longer in talks to acquire the cancer drug developer Revolution Medicines.<stembedurl>https://www.stocktwits.com/TopCharts/message/642896481</stembedurl><h2 class="st-heading-2">Iovance Pipeline</h2>In the three months through the end of September, Iovance reported total product revenue of $68 million, including about $58 million from Amtagvi sales in the U.S. Amtagvi is FDA-approved for the treatment of metastatic melanoma.In November, the company said that it expects full year 2025 revenue of $250 million to $300 million. 2025 marks the first full calendar year of Amtagvi sales. Analysts on average expect the company to report total revenue of $259.45 million.<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> has fallen 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/whats-driving-the-uptick-in-evtv-stock-today/cmy7yYCR4hh">What’s Driving The 38% Uptick In EVTV Stock Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Iovance Biotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IOVA Shares Jump 8% — What’s Retail Expecting?

Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.

Equity

Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.


Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.4% - What's Next?

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.4% - Here's What Happened...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1% - Here's What Happened

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1% - Should You Sell...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7% - Still a Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 8.7% - Here's Why...

Iovance Biotherapeutics, Inc. $IOVA Position Increased by Squarepoint Ops LLC

Squarepoint Ops LLC grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 115.2% in the 2nd quarter, according to the company in its most recent Form 13F filing...

Mirador Capital Partners LP Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA

Mirador Capital Partners LP purchased a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the...

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7% - Should You Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7% - What's Next...

Voss Capital LP Acquires New Shares in Iovance Biotherapeutics, Inc. $IOVA

Voss Capital LP acquired a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities...

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IOVA News

IOVAIovance Biotherapeutics Inc